Azad Babak 4
4 · GoodRx Holdings, Inc. · Filed Dec 13, 2021
Insider Transaction Report
Form 4
Azad Babak
See Remarks
Transactions
- Sale
Class A Common Stock
2021-12-09$42.19/sh−8,430$355,630→ 5,300 total - Sale
Class A Common Stock
2021-12-09$42.68/sh−300$12,804→ 5,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-09−12,500→ 275,000 totalExercise: $5.94Exp: 2030-01-30→ Class A Common Stock (12,500 underlying) - Exercise/Conversion
Class A Common Stock
2021-12-09$5.94/sh+12,500$74,250→ 17,500 total - Sale
Class A Common Stock
2021-12-09$40.96/sh−3,770$154,412→ 13,730 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of December 9, 2020, as amended September 2, 2021.
- [F2]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.65 to $42.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.66 to $42.72. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019.